Home › All Companies › APTN

ADAPTIN BIO, INC. (APTN)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-06

Key Insights

  • Adaptin Bio, Inc. has announced that its common shares have been approved for quotation on the OTCQB® Venture Market, which provides investors with increased visibility and access to the company's stock.
  • As an emerging growth company, Adaptin Bio has elected not to use the extended transition period for complying with new or revised financial accounting standards, indicating a commitment to transparency and timely reporting.
  • The company's headquarters are located in Charlotte, North Carolina, suggesting a potential focus on the southeastern U.S. market and regional business development opportunities.
Sentiment: Positive Significance: 6/10
View Original Filing →
Annual Report Filed: 2026-04-01

Key Insights

  • The company has been active in subsequent events, including two private placements in February and March 2026 involving the issuance of common stock and warrants.
  • The company granted stock options and performance shares to directors, officers, and consultants during the fiscal year 2025.
  • The company had several debt instruments outstanding, including secured promissory notes, private exchange notes, and convertible debt, which were converted or exchanged during the fiscal year 2025.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.